^
Association details:
Biomarker:BRAF wild-type
Cancer:Cutaneous Melanoma
Drug:Opdivo (nivolumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Title:

Systemic Therapy for Melanoma: ASCO Guideline

Published date:
03/31/2020
Excerpt:
In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma....For patients with resected stage IIIA/B/C/D disease that is BRAF wild type, the following options should be offered (in no particular order): nivolumab × 52 weeks OR pembrolizumab × 52 weeks....For patients with BRAF wild-type unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order): ipilimumab plus nivolumab followed by nivolumab OR nivolumab OR pembrolizumab...(Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).
DOI:
10.1200/JCO.20.00198